Knights of Columbus partners with Medishare to provide physical therapy and prosthetic limbs
WASHINGTON, Aug. 4 /PRNewswire-USNewswire/ -- The Knights of Columbus today announced that it will come to the aid of every Haitian child who lost a limb in the January earthquake that destroyed much of their country and claimed nearly a quarter of a million lives. Many thousands more were seriously injured, including hundreds of children who lost arms and legs in the tragedy.
The Knights of Columbus has taken a special interest in helping those injured in Haiti. Working in partnership with the Global Wheelchair Mission, the Knights have so far provided more than 1,000 wheelchairs to those injured, including many children. One thousand more wheelchairs are slated for delivery over the next several months, for a total of more than 2,200.
Today the Knights of Columbus announced a new program - "Hope for Haiti's Children" - to make assistance available to every child in Haiti who lost a limb in the earthquake. The Board of Directors of the Knights of Columbus approved a resolution last weekend that commits the organization to providing prosthetic limbs and therapy over the next two years for all the approximately 800 children who lost an arm or leg in the earthquake. The estimated cost of providing the prosthetic limbs and therapy is $1 million.
News conference participants included the Supreme Knight of the Knights of Columbus, Carl A. Anderson; Prof. Robert Gailey, PhD, PT, director of rehabilitation services for Medishare; Mike Corc
SOURCE Knights of Columbus
Copyright©2010 PR Newswire.
All rights reserved
Related medicine technology :
1. UCLA Program Aims to Revolutionize Kidney Transplants
2. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
3. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
4. Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma
5. Phase 2a Multi-Dose Study Initiated by MedImmune in Patients With Asthma to Further Expand Anti-Interleukin-9 Program
6. Avicena Scientific Collaborator Advances Program for Using Energy Enhancing Molecules to Treat Neuromuscular Diseases
7. Diamyd Updates Gene Therapy Program and Outlines Plans for Phase I Clinical Trial for Treatment of Cancer Pain
8. Memory Pharmaceuticals Commences Phase 1 Clinical Program for R4996/MEM 63908
9. King Pharmaceuticals and Palatin Technologies Delay Immediate Plans for Phase 3 Clinical Program With Bremelanotide for Erectile Dysfunction
10. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
11. Raptor Pharmaceuticals Provides Update of Product Programs